Skip to main content
S&P 5007,663.43-1.21%DOW52,867.98+0.02%NASDAQ26,008.86-2.60%BTC$81,395.00-3.35%ETH$2,391.93-3.37%GOLD$4,036.20-0.60%OIL$99.27-0.20%
Smart Investors Daily
SID Premium
SN

OTC · SNPHY

Santen Pharmaceutical Co., Ltd.

Healthcare · Drug Manufacturers - General

$10.77

Down-$0.43 (-3.82%)

Updated Oct 23, 2026, 2:35 AM

SID Score

6.1/10

Composite research score

Smart Money

46/100

Neutral

Market cap
3.5B
P/E ratio
16.37
Dividend yield
2.39%
52-week range
— – —
Volume
601
Avg. volume
12.41K

Price performance · SNPHY

SNPHY price history

1M range · 0 trading sessions · Daily adjusted prices

SNPHY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SNPHY news

The latest Smart Investors Daily articles mentioning SNPHY.

Stock researchCompany · Overview

SNPHY research

Overview

Company profile and research snapshot.

Company profile

SANTEN PHARM CO UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.61
Implied upside
—
Analysts
13
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Santen Pharmaceutical (TSE:4536) Stock Could Be Undervalued On Current Earnings

Santen Pharmaceutical has delivered a strong run over the past few years, which puts a spotlight on whether the current share price is still grounded in its earnings power. With the stock last closing at ¥1,738, the key issue for you is whether that level is adequately supported by what the business is generating in profit today. The share price has gained 43.8% over 3 years, which makes it important to ask if that rise lines up with the earnings that underpin the stock. The group focuses on...

Yahoo · Oct 1, 2026

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)Secures scalable commercial IOL manufacturing capacity for its Phase 3 lead product candidate, the BIM-IOL SystemAccelerates pathway to adding premium lens options into its IOL-based drug delivery systemSpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By